Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sofosbuvir + daclatasvir for moderate to severe COVID-19
IRCT20200128046294N2Phase 3Completed
- Sponsor
- Digestive Disease Research Institute
- Start
- Mar 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of sofosbuvir and daclatasvir in coronavirus disease 2019 (COVID-19), sponsored by Digestive Disease Research Institute. Started Mar 2020; status: completed.
02
Drugs
sofosbuvirdaclatasvir
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on IRCT20200128046294N2.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20200128046294N2.